Sugi Predict

Sugi Predict / Compounds / Amitifadine

Amitifadine

Amitifadine

SCHEMBL4187671

Cl.Clc1ccc([C@]23CNC[C@H]2C3)cc1Cl

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

SLC6A2SLC6A3SLC6A4

The experimentally established mechanism targets of Amitifadine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ SLC6A2 known ✓ P23975 15/20 1.00
▸ SLC6A4 known ✓ P31645 15/20 1.00
▸ SLC6A3 known ✓ Q01959 15/20 1.00
▸ KCNH2 Q12809 6/20 0.97
▸ CYP1A2 P05177 5/20 0.97
▸ CYP2D6 P10635 5/20 0.97
▸ CYP3A4 P08684 4/20 0.97
▸ CYP2C19 P33261 3/20 0.97
▸ CYP2C9 P11712 2/20 0.97
▸ CYP1A1 P04798 4/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Amitifadine SCHEMBL4552778 1.00 SLC6A2 (1.00) SLC6A2SLC6A4SLC6A3KCNH2CYP1A2
Amitifadine SCHEMBL677553 1.00 SLC6A2 (1.00) SLC6A2SLC6A4SLC6A3KCNH2CYP1A2
Amitifadine SCHEMBL30037571 1.00 SLC6A2 (1.00) SLC6A2SLC6A4SLC6A3KCNH2CYP1A2
Amitifadine SCHEMBL4184473 1.00 SLC6A2 (1.00) SLC6A2SLC6A4SLC6A3KCNH2CYP1A2
Amitifadine SCHEMBL30255318 1.00 SLC6A2 (1.00) SLC6A2SLC6A4SLC6A3KCNH2CYP1A2
Amitifadine SCHEMBL8213058 0.98 SLC6A2 (1.00) SLC6A2SLC6A4SLC6A3KCNH2CYP1A2
Amitifadine SCHEMBL2855353 0.98 SLC6A2 (1.00) SLC6A2SLC6A4SLC6A3KCNH2CYP1A2
Amitifadine SCHEMBL378061 0.98 SLC6A2 (1.00) SLC6A2SLC6A4SLC6A3KCNH2CYP1A2
Amitifadine SCHEMBL9604846 0.98 SLC6A2 (1.00) SLC6A2SLC6A4SLC6A3KCNH2CYP1A2
Amitifadine SCHEMBL12313135 0.98 SLC6A2 (1.00) SLC6A2SLC6A4SLC6A3KCNH2CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200054601-A1 NOVEL METHODS ETHISMOS RESEARCH, INC. 2020-02-20 — — US claimed
US-9566264-B2 Combinations and methods EUTHYMICS BIOSCIENCE, INC. (US) 2017-02-14 — — US claimed
US-20150005359-A1 NOVEL COMBINATIONS AND METHODS ETHISMOS RESEARCH, INC. 2015-01-01 — — US claimed
US-12485088-B2 Rapidly-orodispersible tablets having an interior cavity Aprecia Pharmaceuticals LLC (US) 2025-12-02 — — US disclosed
US-20250276066-A1 METHODS, COMPOSITIONS AND COMPOUNDS FOR TREATING AGE-RELATED DISEASES AND CONDITIONS GERO PTE LTD (SG) 2025-09-04 — — US disclosed
US-12324856-B2 Oral drug dosage form comprising drug in the form of nanoparticles Triastek, Inc. (CN) 2025-06-10 — — US disclosed
US-12257233-B2 Methods ETHISMOS RESEARCH, INC. (US) 2025-03-25 — — US disclosed
EP-4512394-A2 DOSAGE FORMS AND USE THEREOF Triastek, Inc. (CN) 2025-02-26 — — EP disclosed
US-20240408023-A1 DOSAGE FORMS OF CONTROLLED RELEASE AT SPECIFIC GASTROINTESTINAL SITES Triastek, Inc. (CN) 2024-12-12 — — US disclosed
US-20240409514-A1 METHODS FOR INHIBITING NATIVE AND PROMISCUOUS UPTAKE OF MONOAMINE NEUROTRANSMITTERS ETHISMOS RESEARCH, INC. (US) 2024-12-12 — — US disclosed
EP-4171518-B1 RAPIDLY-ORODISPERSIBLE TABLETS HAVING AN INTERIOR CAVITY Aprecia Pharmaceuticals LLC (US) 2024-12-11 — — EP disclosed
US-8877798-B2 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders NEUROVANCE, INC. (US) 2014-11-04 — — US disclosed
EP-2719384-A1 Novel 1 -naphthyl-3-azabicyclo[3.1.0]hexanes:preparation and use to treat neurophychiatric disorders Euthymic Bioscience, Inc. (US) 2014-04-16 — — EP disclosed
US-20140039029-A1 PREPARATION AND USE OF (+)-1-(3,4-DICHLOROPHENYL)-3-AZABICYCLO[3.1.0]HEXANE IN THE TREATMENT OF CONDITIONS AFFECTED BY MONOAMINE NEUROTRANSMITTERS ETHISMOS RESEARCH, INC. 2014-02-06 — — US disclosed
US-20130345439-A1 Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders OTSUKA AMERICA PHARMACEUTICAL, INC. 2013-12-26 — — US disclosed
US-8461196-B2 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders DOV PHARMACEUTICAL 2013-06-11 — — US disclosed
US-20120302619-A1 Novel 1-aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders OTSUKA AMERICA PHARMACEUTICAL, INC. 2012-11-29 — — US disclosed
US-20120258994-A1 Preparation and Use of (+)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane In The Treatment of Conditions Affected by Monoamine Neurotransmitters ETHISMOS RESEARCH, INC. 2012-10-11 — — US disclosed
US-20090233978-A1 Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders OTSUKA AMERICA PHARMACEUTICAL, INC. 2009-09-17 — — US disclosed
US-20070082940-A1 Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders OTSUKA AMERICA PHARMACEUTICAL, INC. 2007-04-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130345439-A1 Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders HTR3C, HTR1B, HTR2C SLC6A2 276/4885SLC6A4 221/4885SLC6A3 92/4885
US-20120302619-A1 Novel 1-aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders HTR3C, HTR1B, HTR2C SLC6A2 276/4885SLC6A4 221/4885SLC6A3 92/4885
US-20120258994-A1 Preparation and Use of (+)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane In The Treatment of Conditions Affected by Monoamine Neurotransmitters COMT, SLC6A3, HTR3A SLC6A2 11/4885SLC6A4 25/4885SLC6A3 2/4885
US-12257233-B2 Methods H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ADH1C, HSD3B1 SLC6A2 527/4885SLC6A4 385/4885SLC6A3 196/4885
US-12324856-B2 Oral drug dosage form comprising drug in the form of nanoparticles CYP2D6, CYP3A5, CYP3A7 SLC6A2 210/4885SLC6A4 268/4885SLC6A3 273/4885
US-20070082940-A1 Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders HTR3C, HTR1B, HTR2C SLC6A2 276/4885SLC6A4 221/4885SLC6A3 92/4885
US-20090233978-A1 Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders HTR3C, HTR1B, HTR2C SLC6A2 276/4885SLC6A4 221/4885SLC6A3 92/4885
US-20200054601-A1 NOVEL METHODS CHRNA5, CHRNB3, CHRNA3 SLC6A2 103/4885SLC6A4 117/4885SLC6A3 31/4885
US-20240409514-A1 METHODS FOR INHIBITING NATIVE AND PROMISCUOUS UPTAKE OF MONOAMINE NEUROTRANSMITTERS SLC18A2, SLC6A2, SLC18A3 SLC6A2 2/4885SLC6A4 5/4885SLC6A3 4/4885
US-20140039029-A1 PREPARATION AND USE OF (+)-1-(3,4-DICHLOROPHENYL)-3-AZABICYCLO[3.1.0]HEXANE IN THE TREATMENT OF CONDITIONS AFFECTED BY MONOAMINE NEUROTRANSMITTERS COMT, SLC6A3, HTR3A SLC6A2 11/4885SLC6A4 25/4885SLC6A3 2/4885
US-20150005359-A1 NOVEL COMBINATIONS AND METHODS SIGMAR1, ADH1C, ADH1A SLC6A2 530/4885SLC6A4 179/4885SLC6A3 205/4885
US-20250276066-A1 METHODS, COMPOSITIONS AND COMPOUNDS FOR TREATING AGE-RELATED DISEASES AND CONDITIONS UPF1, NLN, BRCA1 SLC6A2 3225/4885SLC6A4 3731/4885SLC6A3 3775/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.